Anti-Aging Drug Discovery Targeting HIF-1α

Hypoxia-inducible factor 1-alpha (HIF-1α) is a master regulator of oxygen homeostasis and energy metabolism. It is normally degraded under normoxic conditions but stabilized under hypoxia, leading to the transcription of genes involved in angiogenesis, glucose metabolism, and cell survival. Vascular aging is characterized by structural and functional changes that can lead to hypertension, atherosclerosis, and other cardiovascular diseases. HIF-1α is emerging as an important factor in the progression of vascular aging through its regulation of vascular remodeling and inflammation.

Fig. 1 Schematic illustration of HIF's role in homeostasis (physiological conditions) compared with the pathological situation (age-associated diseases included). (Alique M, et al., 2020)

At CD BioSciences, we specialize in anti-aging drug discovery. We focus on the HIF-1α signaling pathway to help clients develop innovative therapeutics. Additionally, we provide a range of customized experimental models to facilitate the development of effective therapeutic solutions.

How Do We Develop Anti-Aging Drugs Targeting HIF-1α?

HIF-1α stabilizers

We assist clients in developing HIF-1α stabilizers, which enhance the stability and activity of HIF-1α under normoxic conditions. Our team helps clients design and synthesize small molecule stabilizers to protect HIF-1α from degradation, enhancing its cytoprotective functions. We assess the anti-aging effects of HIF-1α stabilizers in various cell types, focusing on their ability to promote cellular health, increase stress resistance, and enhance metabolic functions. We also use aging animal models to evaluate the effects of HIF-1α stabilizers on aging-related phenotypes, lifespan, and healthspan.

What Experimental Models Do We Use in Developing Anti-Aging Drug Targeting HIF-1α?

CD BioSciences offers a range of cellular and animal models to study the role of the HIF-1α signaling pathway in aging and to test the efficacy of drug candidates.

Cellular models

• Endothelial cells. We utilize primary human endothelial cells to evaluate the effects of drugs targeting the HIF-1α signaling pathway. Our models allow clients to assess cellular responses such as proliferation, migration, and angiogenesis, providing insights into the therapeutic potential of targeted drugs in aging.
• Vascular smooth muscle cells (VSMCs). Aging leads to VSMC dysfunction, which contributes to cardiovascular diseases. We help clients study the effects of drugs targeting the HIF-1α signaling pathway on VSMC behavior, focusing on processes such as cell differentiation and contractility. Our services are essential for understanding how these drugs extend vascular aging.

Animal models

• Caenorhabditis elegans model. We utilize the nematode C. elegans as a model to investigate the effects of drugs targeting the HIF-1α signaling pathway on longevity and healthspan. Our services provide valuable insights into the molecular mechanisms underlying aging and the potential for different anti-aging interventions.
• Mouse models. We use genetically modified mice to study the impact of HIF-1α modulation on age-related physiological changes. Our in vivo services allow clients to assess the systemic effects of drugs targeting the HIF-1α signaling pathway, including their impact on lifespan, metabolic health, and aging-related diseases.

Targeting HIF-1α in Vascular Aging

Vascular aging is a critical aspect of the overall aging process and is characterized by endothelial dysfunction, vascular stiffness, and increased risk of cardiovascular events. We are committed to helping clients develop anti-aging drugs targeting the HIF-1α signaling pathway to examine whether they mitigate these age-related changes, such as enhancing endothelial function, promoting angiogenesis, and reducing vascular inflammation.

CD BioSciences strives to help clients explore the potential of the HIF-1α pathways to combat the effects of aging. Our comprehensive approach, utilizing diverse experimental models and innovative drug development strategies, makes us a reliable partner in anti-aging research. If you are interested in our services, please feel free to contact us or make an online inquiry.

References

1. Alique M, et al. Hypoxia-Inducible Factor-1α: The Master Regulator of Endothelial Cell Senescence in Vascular Aging. Cells, 2020, 9 (1): 195.
2. Mylonis I, et al. Specific Inhibition of HIF Activity: Can Peptides Lead the Way? Cancers (Basel), 2021, 13 (3): 410.